Back

TETmedical appoints Marc Lebel and Patrick McBrayer to board

Verifying
  • TETmedical appointed Marc Lebel and Patrick A. McBrayer to its Board of Directors.
  • June 15, 2026: FDA granted NSE-FAST® Breakthrough Device Designation.
  • TETmedical plans a multi-center pivotal study in the fourth quarter of 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.